gsk stock forecast 2030:Why invest in GSK?
Why invest in GSK?
Wearecommittedtoworktowardsanetzero,naturepositive,healthierplanet,withambitiousgoalssetfor2030and2045.。其他文章還包含有:「Analystconsensus」、「CitihikestargetpriceforGSKbutstays'neutral'」、「GlaxoSmithKline(GSK)ShareForecast&PriceTarget」、「GlaxoSmithKlineStockForecast」、「GSKplc(GSK)stockforecastandpricetarget」、「GSKplc-Forecast,PriceTarget」、「GSK」、「StockForecast&PricePr...
查看更多 離開網站Analyst consensus
https://www.gsk.com
GSK share price · Share price calculators (GBp/USD) · Dividend calculators (GBp ... 2027, 2028, 2029, 2030, 2031, 2024-2028 n= Turnover - Vaccines ex pandemic ...
Citi hikes target price for GSK but stays 'neutral'
https://www.sharecast.com
Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1535 ...
GlaxoSmithKline (GSK) Share Forecast & Price Target
https://www.tipranks.com
GlaxoSmithKline Share forecast & analyst price target predictions based on 14 analysts offering 12-months price targets for GSK in the last 3 months.
GlaxoSmithKline Stock Forecast
https://walletinvestor.com
Based on our forecasts, a long-term increase is expected, the GSK stock price prognosis for 2029-06-15 is 1632.294 GBX. With a 5-year investment, the revenue ...
GSK plc (GSK) stock forecast and price target
https://finance.yahoo.com
GSK plc (GSK) stock forecast and price target. Find the latest GSK ... $2030 per ounce. Analyst Report: GSK plc.
GSK plc - Forecast, Price Target
https://fintel.io
The average one-year price target for GSK plc - Depositary Receipt (Common Stock) is $50.185. ... 2030. Although past performance does not guarantee future ...
GSK
https://stocknews.com
The global specialty pharmaceuticals market is estimated to reach $965.54 billion by 2030, expanding at a CAGR of 39.8%. Further, rising R&D ...
Stock Forecast & Price Prediction 2025
https://coincodex.com
This Market Could Be Worth $10 Billion by 2030
https://www.fool.com
The first was U.K.-based pharmaceutical giant GlaxoSmithKline. Pfizer (PFE) and Sanofi (SNY 0.77%) followed soon after, in that order. The RSV ...